Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children

11 Feb, 2021

Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children
Photo by NeONBRAND on Unsplash

– Day One Biopharmaceuticals announced a $130m Series B financing round bringing total investment in the company to $190m.
– The round was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors.
– Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.
– Proceeds from the Series B financing will allow Day One to accelerate and expand its search and evaluation capabilities, support drug development efforts and continue advancing commercial launch plans for the Company’s lead program, DAY101.

Biopharma Biotechnology Health Care Medical North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: